Photo from wikipedia
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old… Click to show full abstract
Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion of B-lymphocytes. Herein we describe the case of a 56-year-old female who developed odynophagia and bloody diarrhea following treatment with ocrelizumab. This was characterized endoscopically by ulcerations in the esophagus and colon. The patient was treated with high-dose intravenous glucocorticoids with good clinical response.
Keywords:
bowel disease;
inflammatory bowel;
like illness;
disease like;
ocrelizumab induced;
induced inflammatory
Journal Title: Annals of Gastroenterology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Annals of Gastroenterology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!